Since MMP-9 activity is associated with tumor invasion and metastasis (335), the rationale is that andecaliximab will inhibit extracellular matrix protein degradation and angiogenesis, while nivolumab will interfere with the PD-1/PD-L1 axis. This evidence concerns the gene PDCD1 and neoplasm.